Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- UNKNOWN
- Phase
- PHASE2
Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms
- Status
- COMPLETED
- Phase
- N/A
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- Status
- SUSPENDED
- Phase
- PHASE2/PHASE3
Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
- Status
- UNKNOWN
- Phase
- PHASE2
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
- Status
- TERMINATED
- Phase
- NA
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
- Status
- COMPLETED
- Phase
- PHASE1
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Cetuximab for Elderly Patients With mCRC
- Status
- TERMINATED
- Phase
- PHASE2
Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
- Status
- COMPLETED
- Phase
- PHASE1
Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
- Status
- COMPLETED
- Phase
- NA
Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
- Status
- COMPLETED
- Phase
- PHASE2
Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer
- Status
- COMPLETED
- Phase
- N/A